1:5 Stock Split: Small Cap Pharma Stock Declares Record Date, Gains 2178% In 5-Yrs

Small cap stock operating in pharmaceuticals sector, Gujarat Themis Biosyn Ltd on September 20 after the market hours fixed October 10, 2023 as the record date for sub-division of shares. Gujarat Themis shares soared 0.98% intraday on Thursday. Gujarat Themis shares witnesses a spurt in volume by 2.11 times on Sept 15 and by 3.46 times on September 14. Earlier, the company recommended a dividend of Re 1/share for the financial year ended March 2023. Gujarat Themis stock rallied 332% in last 3-years.

Gujarat Themis Sets Record Date For Stock Split: As per the BSE filing of the company dated Sept 20, "With reference to the captioned subject and in terms of Regulation 42 of the SEBI Listing Regulations, the Company has fixed Tuesday, 10th October, 2023 as the 'Record Date' for the purpose of determining the eligibility of Shareholders for the purpose of sub-division/split of every one fully paid-up Equity share having face value Rs. 5/- (Rupees Five only) each in the authorised share capital of the Company, into 5 (five) fully paid-up Equity shares having face value of Rs. 1/-(Rupee One only) each, as approved by the shareholders at the 42nd Annual General Meeting of the Company held on 9th September, 2023."

Gujarat Themis Stock Performance & Outlook: Current market price of Gujarat Themis share is Rs 887.00 per share on BSE. Its 52-week high price is Rs 921.05 per share and 52-week low price is Rs 572.10 per share, respectively. Its market capitalisation is Rs 1288.70 crore. Gujarat Themis stock gained 34% in last 6-months, soared 14% YTD, rose 47% in last 1-year, and jumped 2176% in last 5-years.

Gujarat Themis Financials: The company for the quarter ended June 30, 2023 announced its net sales at Rs 49.59 crore, up 10.33% as against Rs 44.94 crore declared in June 2022. Its quarterly net profit has been declared at Rs 17.72 crore in June 2023, down 0.27% as against Rs 17.77 crore in June 2022. The company announced its EBITDA at Rs 24.58 crore in June 2023, up 1.57% as compared to Rs 24.20 crore in June 2022.

Gujarat Themis About: Incorporated in 1981 as a joint sector company with GIIC Ltd and Chemosyn (P) Ltd. It commenced production in August, 1985 by producing Erythromycin and Erythromycin salts and formulations. The Company was taken over during June 1991 by Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug Companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. The Company entered into Technical & Financial collaboration with Yuhan Corporation, South Korea. With Yuhan's know-how, GTBL became India's first Company to start commercial production of Anti-tuberculosis drug Rifampicin, according to its official website.

Disclaimer

The stock just highlights the stock split and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for any losses. Please consult a professional advisor.